Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Next Previous
Trial Profile

A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 Followed by a Randomized Controlled Trial of DFMO With or Without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMXT 1501 (Primary) ; Eflornithine (Primary)
  • Indications Diffuse intrinsic pontine glioma; Ewing's sarcoma; Neuroblastoma; Osteosarcoma; Rhabdoid tumour
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Feb 2025 Planned initiation date changed from 1 Feb 2025 to 1 Oct 2025.
  • 27 Dec 2024 Planned End Date changed from 1 Dec 2034 to 1 Feb 2035.
  • 27 Dec 2024 Planned primary completion date changed from 1 Dec 2032 to 1 Feb 2033.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top